Previous close | 232.98 |
Open | 235.91 |
Bid | 228.02 x 200 |
Ask | 229.21 x 200 |
Day's range | 224.39 - 235.91 |
52-week range | 119.76 - 322.67 |
Volume | |
Avg. volume | 571,851 |
Market cap | 4.789B |
Beta (5Y monthly) | -0.44 |
PE ratio (TTM) | N/A |
EPS (TTM) | -19.99 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 394.54 |
CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 7 new employees, in each case with a grant date of April 15, 2024, as equity inducement awards under the terms of the company's 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The equity a
In this article, we will take a detailed look at Latest Insider Selling in April 2024: 10 Stocks to Watch. For a quick overview of the 5 such stocks, read our article Latest Insider Selling in April 2024: 5 Stocks to Watch. Wall Street analysts and wise investors often keep a close eye on insider buying and selling, […]
Rezdiffra Rezdiffra product image Rezdiffra is the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) First patients have received Rezdiffra via Madrigal’s specialty pharmacy network CONSHOHOCKEN, Pa., April 09, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Rezdiffra (resmetirom) is now available in